Loading organizations...
§ Private Profile · Laguna Hills, CA, USA
Biotechnology company developing tumor-activated immunotherapies for solid cancers and autoimmune diseases.
Amberstone Biosciences is an Irvine, California-based biopharmaceutical company that discovers and develops conditionally active immunotherapeutics designed to selectively target solid cancers while minimizing systemic dose toxicity. The enterprise utilizes proprietary single-cell discovery platforms to create specialized treatments that activate exclusively within the tumor microenvironment rather than harming healthy tissues. Operating as an early-stage clinical venture, the organization has raised a total of $13.22 million in capital, which includes a $12 million Series A financing round secured in January 2022. This financial backing was provided by a syndicate of institutional investors that includes Viva BioInnovator, Co-win Ventures, Sinovation Ventures, and Mass General Brigham Ventures. The firm is also guided by a scientific advisory board featuring prominent industry figures such as Moderna co-founder Robert Langer. Amberstone Biosciences was founded in 2018 by George Wu and Weian Zhao.
Amberstone Biosciences has raised $12.0M across 1 funding round.
Amberstone Biosciences has raised $12.0M in total across 1 funding round.
Amberstone Biosciences has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 3, 2022 | $12M Series A | XIN Huang, Peter WU | Changrong Capital, Lifespan Investments | Announced |
Amberstone Biosciences has raised $12.0M in total across 1 funding round.
Amberstone Biosciences's investors include Xin Huang, Peter Wu, ChangRong Capital, Lifespan Investments.